Kenya BioVax Institute Limited, 40779, Nairobi (2025)

21/11/2025

Kenya BioVax Institute (KBI) today hosted a courtesy call led by Anne-Claire Amprou, the French Ambassador for Global Health, accompanied by Dr. Serawit Bruck Landais, Global Health Advisor for East Africa and Somalia. The delegation was received by KBI’s CEO, Dr. Wesley Ronoh, together with senior leadership, including Dr. Cecilia Wanjala (GM, Commercial Services), Dr. Serah Muteru (GM, Regulatory Affairs, Product Quality & Safety), and Prof. Richard Oduor (GM, Research & Technology Transfer). Discussions focused on strategic areas of collaboration, including technology transfer of KBI’s preferred antigen portfolio, strengthening research and development capabilities, and enhancing tech-transfer readiness. The meeting also explored Kenya’s evolving regulatory landscape in preparation for local vaccine manufacturing, as well as opportunities for market access through the African Pooled Procurement Mechanism. Additionally, the teams deliberated on KBI’s potential participation in the upcoming high-level France–Kenya Summit in May 2026, where KBI could showcase its growing role in advancing local vaccine production and regional health security.

🇰🇪 🇫🇷🇰🇪 French Embassy in Kenya and Somalia

19/11/2025

Happy International Men’s Day 2025! 🇰🇪

Today, we celebrate the men who continue to contribute to stronger families, resilient communities, and a healthier nation. At Kenya BioVax, we recognize and appreciate the dedication, leadership, and commitment of men across our workforce and within the wider scientific, healthcare, and public service ecosystems.

Here’s to all the men driving positive change, uplifting others, and shaping a better future for Kenya and Africa.

Happy International Men’s Day!

18/11/2025

Leadership Transition: Dr. Ronoh Takes Over as CEO

Dr. Cecilia Wanjala, the Acting CEO of Kenya BioVax Institute Limited, has officially handed over leadership to the substantive CEO, Dr. Wesley Ronoh, in a ceremony presided over by the Chairman of the Board of Directors, Dr Charles Githinji, at the Kenya BioVax headquarters. Dr. Ronoh brings over 25 years of rich experience in the pharmaceutical sector development across Africa, having most recently served as the Market Shaping Lead for Partnerships for African Vaccine Manufacturing (PAVM) at Africa CDC, where he led the Market Design and Demand Intelligence Bold Programme and supported the development of the African vaccine procurement pooling mechanism.

A seasoned pharmacist with postgraduate training in Medicinal Chemistry and an MBA, Dr. Ronoh has held senior advisory roles with GIZ, the EU, EAC, and SADC, contributing significantly to regional health product policies, investment frameworks, and access-to-medicines strategies. His extensive expertise in life science product development, regulatory affairs, intellectual property, strategic planning, and private sector development positions Kenya BioVax for strengthened leadership as it advances its mandate in local vaccine manufacturing and health security.

The Ministry of Health Kenya Medical Research Institute Pharmacy and Poisons Board Pharmaceutical Society of Kenya

11/11/2025

Kenya BioVax Institute Limited appreciates the continued commitment of the Government of Kenya, through the The Ministry of Health, to advancing local vaccine research, development, and manufacturing as a key pillar of health security and Universal Health Coverage (UHC). We were honoured to participate in a meeting convened by the Principal Secretary for Public Health and Professional Standards, Mary Muthoni, with the International AIDS Vaccine Initiative (IAVI) led by Dr. Kundai Chinyenze. The discussions focused on strengthening collaboration in vaccine innovation, research, and capacity development to accelerate Kenya’s journey toward vaccine self-sufficiency. We value the partnership and collective effort demonstrated by IAVI, the Kenya National Public Health Institute (NPHI), the Pharmacy and Poisons Board, and the Kenya Medical Research Institute in supporting the growth of Kenya’s vaccine ecosystem.

07/11/2025

Building Africa’s Capacity, Credibility, and Confidence in Vaccine Manufacturing

At the Workshop on Chartering the Roadmap to the First Vial, participants were honored to hear from Dr. Mazyanga Lucy Mazaba, Regional Director, Eastern Africa Regional Coordinating Centre, Africa Centres for Disease Control and Prevention (Africa CDC).

In her presentation titled “BioVax’s Place in Africa’s Vaccine Manufacturing: Building Capacity, Credibility, and Continental Confidence,” Dr. Mazaba highlighted the critical role of regional collaboration, institutional strengthening, and regulatory harmonization in advancing Africa’s vaccine manufacturing agenda. She commended Kenya BioVax Institute for its leadership in driving local production and supporting Africa CDC’s vision of vaccine self-reliance under the New Public Health Order.

The workshop also marked the participation of Dr. Wesley Ronoh, the newly appointed Chief Executive Officer of Kenya BioVax Institute, who joined the Board of Directors led by Dr. Charles Githinji and the Senior Management Team in reaffirming Kenya BioVax’s commitment to building a sustainable, credible, and globally competitive vaccine manufacturing ecosystem for Africa. 🌍💉🇰🇪

| | | | | | | | The Ministry of Health Kenya Medical Research Institute

06/11/2025

The Kenya Bio-Vaccine Mission Program in the Republic of Korea 🇰🇷 (23rd–30th October 2025) brought together Kenyan experts and institutions, including the Kenya BioVax Institute 🇰🇪, to benchmark Korea’s world-class vaccine research, manufacturing, and innovation ecosystem. Through visits to Celltrion, the International Vaccine Institute (IVI), KAIST, the Public Contract Development and Manufacturing Organization (PCMO), and the Korea Disease Control and Prevention Agency (KDCA), the delegation—featuring BioVax leadership—explored opportunities in technology transfer, workforce training, and collaborative research to advance Kenya’s Smart Vaccine Manufacturing Facility at Konza Technopolis. The mission strengthened bilateral partnerships, reaffirmed IVI’s commitment to supporting BioVax’s vaccine production agenda, and positioned the Institute as a key driver of Kenya’s journey toward vaccine self-reliance and sustainable health innovation.

🇰🇪🤝🇰🇷

05/11/2025

Harnessing Private Sector Efficiency: Charting the Road to the First Vial

Kenya BioVax Institute Limited today hosted a high-level Workshop on Chartering the Roadmap to the First Vial, bringing together visionary leaders, industry experts, and development partners to discuss practical steps toward Kenya’s goal of local vaccine production. The session provided a collaborative platform to share ideas, align strategies, and strengthen partnerships that will move the country closer to its first locally manufactured vaccine vial.

Keynote Speaker Mr. Joe Sang, Managing Director of Kenya Pipeline Company, delivered an inspiring presentation on harnessing private sector efficiency — emphasizing how strong leadership, innovation, and performance-driven governance can accelerate institutional success. The event was graced by the Kenya BioVax Institute Limited Board of Directors led by Dr. Charles Githinji, together with the Senior Management Team, and honored guests including Dr. Bernard Olayo from the World Bank Africa.

Together, we continue to build momentum toward a stronger, self-reliant, and globally competitive vaccine ecosystem for Kenya and the region. 🇰🇪💉

28/10/2025

🌿 At Kenya BioVax Institute, we’re on a mission to strengthen Africa’s health sovereignty through local vaccine production and biopharmaceutical innovation. 💉

Ready to make an impact? Explore opportunities to work, collaborate, or partner with us.

Visit our website for more details 👇
🔗 [Website link: https://biovax.go.ke/]

23/10/2025

Towards a Regional Hub for Bioequivalence and Pharmaceutical Research in East Africa

Kenya BioVax Institute, represented by its Chairman, Dr. Charles Githinji, participated in the National Stakeholders’ Consultative Meeting on the Establishment of the East African Community Regional Centre of Excellence in Bioequivalence and Pharmaceutical Research (EAC RCoE-BPR). The meeting, jointly convened by the Pharmacy and Poisons Board (PPB), Kenya BioVax Institute (KBI), and the University of Nairobi (UoN), brought together key stakeholders from the National Quality Control Laboratory (NQCL), Ministry of Health, State Department for Public Health, State Department for the East African Community, and the Pharmaceutical Society of Kenya (PSK).

The proposed Centre seeks to strengthen regional capacity in bioequivalence testing, pharmaceutical research and development, and specialist training to advance the quality, safety, and efficacy of medicines within the East African region. By fostering collaboration among academia, industry, and government agencies, the EAC RCoE-BPR will play a pivotal role in promoting pharmaceutical innovation, regulatory harmonization, and self-sufficiency in local manufacturing.

20/10/2025

Happy Mashujaa Day! 🇰🇪

Today we honour the courage, sacrifice, and resilience of Kenya’s heroes—past and present—who built the foundation of our freedom and continue to inspire our nation’s progress.

Let’s keep the spirit of heroism alive in everything we do. 💚🤍❤️🖤

🇰🇪

16/10/2025

We mourn the passing of Rt. Hon. Raila Odinga, EGH (7 January 1945 – 15 October 2025).

A true patriot and visionary leader, he devoted his life to the pursuit of justice, democracy, and a better Kenya for all. His courage, resilience, and unwavering commitment to the people will continue to inspire generations.

Our deepest condolences go to his family, friends, and the entire nation as we honour his remarkable legacy.

May his soul rest in eternal peace.

14/10/2025

The Chairman of the Board of Directors, Dr. Charles Githinji, led members of the KKenya BioVax Institute Limitedon an inspection visit to the Embakasi manufacturing site to assess the ongoing enabling works and overall project progress. Accompanied by the management and technical teams, the Board received detailed briefings on infrastructure development, regulatory readiness, and operational planning milestones. The visit reaffirmed the Board’s commitment to ensuring that the facility meets international standards and remains aligned with Kenya’s goal of achieving local vaccine production capacity. Dr. Githinji commended the teams for their dedication and urged continued collaboration to accelerate completion and operational readiness of the Embakasi facility — a cornerstone in advancing the nation’s health security agenda.

TThe Ministry of HealthKKenya Medical Research Institute

Kenya BioVax Institute Limited

21/11/2025

19/11/2025

18/11/2025

11/11/2025

07/11/2025

06/11/2025

05/11/2025

28/10/2025

23/10/2025

20/10/2025

16/10/2025

14/10/2025

Address

Telephone

Website

Alerts

Contact The Practice

Shortcuts

Share

Category